Agenus (AGEN) News
NASDAQ: AGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
5.97-0.17 (-2.77%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AGEN news summary
We found 6 recent headlines mentioning Agenus (AGEN): 0 in the past week and 2 in the past 30 days, most often from Nasdaq, Business Wire. For price context, AGEN is down 2.77% at $5.97. The most recent story, "Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down", was published by Nasdaq on Nov 6, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Agenus headlines
- Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock DownAGEN's Q3 earnings meet estimates, but a revenue miss weighs on shares as pipeline progress, Armenian drug approvals and new funding emerge as key developments.NasdaqAGEN, TGTX, AMRX, IBRX
- Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN StudyLEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the third quarter ended September 30,…Business Wire
- Agenus to Provide Third Quarter 2026 Financial Report and Development UpdateLEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026…Business Wire
- ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue EstimatesImmunityBio (IBRX) delivered earnings and revenue surprises of +11.11% and +5.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqIBRX, AGEN
- IBRX Stock Outlook After Q1 Results and a New FDA ReviewImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.NasdaqAGEN, IOVA, IBRX
- ImmunityBio: Anktiva Explained and What Comes NextIBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.NasdaqAGEN, IOVA, IBRX